Adlai Nortye ($ANL): RAS Trials, AN4035 and the Funding Reset

01 Three scenarios: a funded oncology pipeline still has to establish a therapeutic window

Constructive scenario — the RAS programs become clinically interpretable

The constructive case is that Adlai Nortye converts a substantially stronger balance sheet into useful early clinical evidence. AN9025 tests an oral pan-RAS(ON) inhibitor with daily and intermittent weekly dosing. AN4035 uses an antibody-drug conjugate to deliver a pan-RAS(ON) inhibitor payload to CEACAM5-enriched tumors. The two programs pursue a related pathway through different delivery strategies, and management’s August update placed their initial clinical data windows in 2027.[2]

In this scenario, dose escalation produces tolerable exposures, pharmacodynamic evidence and preliminary activity sufficient to justify expansion in defined patient groups. The purpose is not merely to show that a compound can be administered, but to establish a practical relationship among dose, exposure, toxicity and antitumor effect. Those elements would make the next clinical development decisions more specific and allow the company to direct capital toward the strongest evidence.

The October 15 collaboration with Lilly and Merck KGaA supports the operating plan for AN4035 by providing cetuximab for the applicable trial sites. Adlai remains the study sponsor. The announcement creates a clearer supply arrangement for an investigational combination; it is not itself a clinical result or a commercialization agreement. In the constructive case, that arrangement helps the trial execute while the actual patient data determine whether the combination rationale is productive.[1]

Middle scenario — development progresses, but evidence matures slowly

A middle outcome would include continued enrollment and dose escalation without an early decisive clinical profile. Phase I studies often need information from several dose levels, sufficient exposure and adequate follow-up before an expansion strategy becomes convincing. For AN9025, the company expects initial daily-arm Phase Ia data in H1 2027, with a possible early look at the weekly arm. For AN4035, its August guidance placed initial clinical data in H2 2027. Those windows are expectations, not guarantees about the content or maturity of results.[2]

Adlai’s June liquidity gives it more room to navigate that interval than its year-end 2025 balance sheet did. However, money provides development capacity rather than a favorable biological outcome. The clinical question remains open even if enrollment, supply and financing proceed according to plan. The more informative update would connect the number of patients treated, selected doses, safety and activity, rather than simply reiterate that a study is ongoing.

Adverse scenario — exposure, toxicity or prioritization disappoints

The adverse case includes a therapeutic window that is too narrow, insufficient activity at tolerable doses, difficulty selecting a regimen, slower recruitment or development spending that produces limited decision-quality evidence. These are material early-stage risks because both principal RAS programs remain investigational. The company’s own announcements identify clinical, regulatory, manufacturing, collaboration and financing uncertainties.[1][2]

There is also a per-share dimension. The June financial position followed equity issuance, and the comparative balance-sheet tables show a larger ordinary-share denominator. Capital can extend the opportunity to develop the pipeline while reducing each pre-existing share’s proportional interest. A scientific success must ultimately be considered together with the spending and ownership required to obtain it, rather than assessed as though the funding had no economic cost.[2]

02 The business: a RAS-focused strategy within a broader oncology portfolio

Adlai Nortye Group is a clinical-stage biopharmaceutical company whose public materials emphasize precision RAS-pathway therapies and next-generation PD-1/PD-L1-pathway immunotherapies. The October corporate description identifies oral AN9025, the CEACAM5-targeting ADC AN4035 and the multifunctional antibody fusion protein AN8025 as central elements. The August update also discusses AN0025 and the deprioritization of AN4005 monotherapy development.[1][2]

The current legal identity differs from the name on older financial statements. The August 19 Form 6-K reports completion of the continuation from the Cayman Islands to Singapore and the name change from Adlai Nortye Ltd. to Adlai Nortye Group Ltd. on July 29, 2026. It states that ADS trading under the new name would begin August 21, with ticker ANL and CUSIP 00704R109 unchanged. Older filings remain relevant historical documents, but their former corporate name is not the current issuer name.[3]

The strategy joins programs that are related at the level of cancer biology but distinct in development risk. AN9025 delivers a small molecule systemically. AN4035 seeks tumor-directed delivery through an antibody conjugate. AN8025 combines immune-modulating components in a fusion protein. AN0025 targets the EP4 receptor to modulate the tumor microenvironment. Success in one program could inform the overall strategy without proving that another molecule, modality or tumor setting will succeed.[1][2]

The financial model is also development-stage. First-half 2026 revenue came from an exclusive AN9025 license agreement with Jiangsu Aosaikang, primarily upfront and development-milestone recognition. It was not revenue from sales of an approved Adlai cancer drug. This distinction matters because licensing revenue can support development without establishing commercial demand for the investigational pipeline.[2]

The business therefore needs to be evaluated through several connected questions: which programs create usable clinical evidence, what rights and obligations attach to each asset, how the portfolio is prioritized, and how much capital is consumed before the next meaningful decision. Pipeline breadth is relevant only when accompanied by sufficient resources and disciplined allocation. An early clinical-stage company can have several mechanisms under study while still depending heavily on a small number of future data packages.

03 October 15: Lilly and Merck KGaA supply cetuximab for the AN4035 study

On October 15, Adlai announced clinical trial collaboration and supply agreements with Eli Lilly and Company and Merck KGaA, Darmstadt, Germany. The agreements concern cetuximab, the anti-EGFR antibody marketed as Erbitux, for use with AN4035 in the ongoing global Phase I study. Lilly will supply cetuximab at no cost to U.S. trial sites; Merck KGaA will do so for the Australian and Chinese sites. Adlai Nortye remains the trial sponsor.[1]

The names of the counterparties require precision. This announcement refers to Merck KGaA, Darmstadt, Germany. It does not refer to the separate U.S. company Merck & Co. Likewise, the disclosed relationship is a trial collaboration and supply arrangement for cetuximab. The release describes the provision of study drug, not a payment to Adlai for commercial rights or a purchase of the AN4035 program.[1]

Scientifically, the combination seeks to inhibit EGFR and RAS signaling while using an ADC to direct the RAS-inhibitor payload toward CEACAM5-expressing tumors. Management presents this as an attempt to broaden the therapeutic window relative to systemic combinations that may face overlapping toxicities. That is the development hypothesis. The Phase I trial evaluates safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy, which are the observations needed to test it.[1]

The announcement says the monotherapy and cetuximab combination arms have a staggered-start timeline. It is therefore important to distinguish an agreement supporting both arms from a statement that every arm has already treated patients or produced results. The trial can accumulate monotherapy information and combination information on different schedules. A later update would be most useful if it made those populations and their exposure clear.[1]

The immediate operational significance is access to the combination drug under the disclosed regional arrangements. The scientific significance remains prospective: whether the combination can achieve a useful effect without an unacceptable toxicity burden. A high-profile supplier can help a study proceed, but the name on the supply agreement cannot substitute for the trial’s own results. The value of the relationship will become clearer through execution and data, not through an assumed endorsement of efficacy.

04 AN4035: tumor-directed RAS inhibition through an ADC

AN4035 is described by Adlai as a CEACAM5-targeting antibody-drug conjugate carrying a pan-RAS(ON) inhibitor payload. The company places it within its RASiCA platform. The intended advantage is selective delivery to tumor cells with the relevant target expression, rather than relying solely on systemic exposure to the unconjugated payload. The October announcement presents preclinical evidence of tumor retention, selectivity and antitumor activity as the rationale for clinical testing.[1]

That design has several development requirements. Target expression must be sufficient and biologically relevant, the conjugate must reach the intended cells, the payload must be delivered in an active form, and the resulting exposure must create a tolerable margin between tumor effect and harm to normal tissue. These are linked but distinct questions. Strong activity in a model can support a clinical hypothesis without establishing an acceptable human dosing window.

The ClinicalTrials.gov record NCT07686445 describes a first-in-human, open-label Phase I program with dose escalation and dose expansion. It includes AN4035 monotherapy and an EGFR-inhibitor combination, with cetuximab described in the study summary. The listed enrollment of 228 is estimated, covering the planned study structure; it is not a statement that this many patients have already been treated. The listed primary and overall completion dates are estimated dates in 2028.[4]

The registry has a separate update clock from company news. Its July 14, 2026 posted version still lists the study as not yet recruiting and gives an estimated September start. The company’s September 8 announcement reports a first patient dosed in Australia and U.S. FDA IND clearance, while the October announcement describes the ongoing global study. The older registry status and the later operating announcements therefore describe different information dates, rather than proving that the reported first dose did not occur.[1][4][7]

The first relevant human observations will concern dose-limiting toxicities, tolerability, exposure, pharmacodynamic changes and preliminary antitumor activity. Monotherapy and combination findings need separate interpretation because adding cetuximab can change both activity and toxicity. A response signal at one dose level would be an early observation; the development decision also requires a dose and schedule that can be used consistently in the intended patients.

Adlai’s August guidance placed initial AN4035 clinical data in H2 2027. That is different from the registry’s estimated study completion in 2028. An early data presentation can precede primary completion and may contain only a portion of the eventual participants or follow-up. The maturity and denominator of the actual presentation will determine how much uncertainty it resolves.[2][4]

05 AN9025: daily and weekly dosing test a different route to the same pathway

AN9025 is an oral pan-RAS(ON) inhibitor in a global Phase I study in advanced or metastatic solid tumors with RAS mutations. Adlai reports first dosing in the U.S. daily arm in February 2026 and the intermittent weekly arm in July, with both arms enrolling in the United States and China. The August release expects initial daily-arm Phase Ia dose-escalation data in H1 2027 and leaves open a possible early look at the weekly arm.[2]

The two schedules are scientifically important because efficacy and tolerability can depend on exposure over time, not just the amount administered at an individual dose. Intermittent dosing could in principle create a different exposure-toxicity relationship from daily administration. Whether that relationship is useful for AN9025 is a question for the study, not an established advantage implied by the existence of a weekly arm.

ClinicalTrials.gov NCT07252479 describes a first-in-human, open-label, multicenter study comprising dose escalation, a food-effect assessment and dose expansion. The record specifies daily or weekly administration in the escalation component and an estimated total enrollment of 118. Its June 8, 2026 posted update lists the study as recruiting. The recorded estimated completion dates in 2028 are distinct from management’s planned initial data window in 2027.[5]

The dose-escalation objective includes identifying a maximum tolerated dose and/or recommended dose for expansion. The subsequent expansion is intended to evaluate activity in selected RAS-mutated tumor settings and further characterize safety, tolerability and pharmacokinetics. This structure highlights why an early response percentage is not the whole data package: dose selection, exposure, adverse events and the patient groups contributing to the signal are central to the next decision.[5]

The food-effect component addresses another practical question for an oral therapy: whether fed and fasting conditions change the pharmacokinetic profile. Such information can influence a feasible dosing regimen without being evidence of antitumor efficacy. A well-defined oral regimen requires consistency and tolerability as well as activity, particularly if the development strategy ultimately includes combination treatment.[5]

AN9025 and AN4035 should consequently be read as separate clinical propositions. The former tests systemic oral dosing; the latter adds antibody-directed delivery and target-expression requirements. Their shared RAS focus gives Adlai a coherent strategic theme, but it does not make the risks redundant. Results from each program need to establish the merits of that molecule, schedule and patient selection on their own terms.

A named competitive reference is Revolution Medicines’ daraxonrasib (RMC-6236). The October 2, 2026 registry update for RASolute 303 describes a randomized, open-label Phase III study in first-line metastatic pancreatic adenocarcinoma, comparing daraxonrasib alone, daraxonrasib plus gemcitabine/nab-paclitaxel, and that chemotherapy alone.[15] The registry of the earlier RASolute 302 study identifies daraxonrasib by its development code, RMC-6236.[16] The contrast with Adlai’s early dose-finding programs is one of development maturity and trial design, not demonstrated superiority. Different populations, regimens and study questions prevent a reliable efficacy ranking from cross-trial response percentages.

06 AN8025, AN0025 and AN4005: portfolio breadth and prioritization

AN8025 is described in the August update as a next-generation trispecific antibody fusion protein derived from an anti-PD-L1 antibody and fused with optimized CD86 and LAG3 variants. Adlai reported an ongoing global Phase I study in Australia and China and targeted completion of dose escalation by the end of 2026. That is a company operating target, not a result already established by the August announcement.[2]

AN0025 is an EP4 antagonist intended to modulate the tumor microenvironment. The same release states that enrollment in the randomized Phase II ARTEMIS study in rectal cancer had completed and follow-up was ongoing. It reports that the study passed a futility analysis in March 2026 and targets topline results in H1 2027. Passing a futility analysis means the program continued under that analysis; it is not equivalent to a positive final efficacy endpoint.[2]

The 2025 annual report specifies a planned ARTEMIS sample of 140 patients, randomized 1:1. Both groups receive standard preoperative chemoradiotherapy and total neoadjuvant treatment with FOLFOX or CAPOX; AN0025 is added in the experimental group. The primary endpoint is the clinical complete response rate six months after the start of radiotherapy.[6]

The earlier evidence comes from a separate open-label Phase Ib study reported in 2023: 28 participants, of whom 25 completed treatment and were evaluated for efficacy. Nine of those 25 (36%) achieved either a pathological complete response or a clinical complete response; among the 15 patients who underwent surgery, four achieved a pathological complete response.[17] These are not ARTEMIS results. The Phase Ib combined response measure differs from ARTEMIS’ clinical-complete-response endpoint, and the small open-label study cannot isolate the benefit of adding AN0025 to the treatment regimen.

This makes ARTEMIS a different kind of development event from an early Phase I update. A randomized Phase II result can address a defined treatment comparison, while first-in-human studies focus more heavily on dose, tolerability and early activity. The timing windows may overlap in 2027, but the evidence questions and interpretive standards differ. Combining all readouts into a single generic “pipeline catalyst” would obscure those distinctions.

AN4005 illustrates a different portfolio decision. Adlai says it is deprioritizing monotherapy development as part of its strategic prioritization, while remaining open to collaboration for combination approaches. It anticipated an update from ongoing expansion cohorts at the 2026 SITC meeting. The company described preliminary safety and activity observations, but its allocation decision shifts the emphasis away from continued standalone monotherapy development.[2]

Deprioritization can conserve resources and sharpen focus, but it also demonstrates that a pipeline chart is not a permanent commitment to advance every listed program. Each asset competes for scientific attention, trial capacity and capital. The useful comparison over time is whether new evidence leads to a clear next development step, a partnership, a narrower program or a decision to stop allocating resources.

For Adlai, the portfolio therefore contains both concentrated RAS ambitions and other immuno-oncology paths. Its financial resources create room to choose among them, but the quality of those choices will matter as much as the number of assets. Broad mechanistic coverage is not itself diversification of clinical success when multiple programs remain dependent on early and uncertain human evidence.

07 June liquidity: $231.886 million across cash and short-term investments

The June 30, 2026 balance sheet reports $132.590 million of cash and cash equivalents and $99.296 million of short-term investments at amortized cost. Their calculated sum is $231.886 million, which the company rounds to $231.9 million in its results commentary. The same balance sheet separately reports $0.080 million of restricted cash, $0.931 million of financial assets at fair value through profit or loss and $4.341 million of long-term equity investments. Those separate assets are not added to the cash-plus-short-term-investment figure.[2]

This classification is important. A bank balance, an amortized-cost investment, a restricted deposit and an equity investment do not necessarily have the same availability, risk or use. A broad total-assets number can say much less about operating flexibility than a clearly defined liquidity measure. Adlai reported total assets of $248.362 million and total liabilities of $33.534 million at June 30, but those totals should retain their accounting meanings rather than become substitutes for cash.[2]

The liability side includes $17.619 million of current interest-bearing bank borrowings and $7.341 million of long-term borrowings, a calculated total of $24.960 million. Current and non-current lease liabilities were $0.772 million and $0.969 million, respectively. Trade payables were $4.610 million. Gross liquidity and gross obligations therefore belong side by side; neither the equity balance nor a simplified cash headline captures every funding claim.[2]

The contrast with the preceding year-end is substantial. The comparative June statements show cash of $8.056 million, restricted cash of $15.730 million and negative shareholders’ equity of $8.322 million at December 31, 2025. At June 30, 2026, shareholders’ equity was positive $214.828 million. That is a changed financial position, not merely a change in how the pipeline is described.[2]

The proper inference is that Adlai had materially greater funding capacity at the June balance-sheet date. It is not that every program was fully funded through approval or that future equity issuance had become impossible. The planned global studies remain at stages where enrollment, dose selection, combinations and later-trial requirements can alter spending. Available capital reduces immediate constraints while leaving scientific and capital-allocation risks intact.

08 Operating cash use, investing flows and the difference between cash and earnings

For H1 2026, Adlai reported operating cash use of $15.354 million, investing cash use of $83.744 million and financing cash inflow of $223.141 million. The cash-flow statement shows beginning cash of $8.056 million, a $124.043 million net increase before foreign-exchange effects and a $0.491 million exchange effect, producing ending cash of $132.590 million. These are cash-flow categories for the period, not interchangeable measures of expense or funding.[2]

The investing outflow is particularly easy to misread alongside the operating figure. A company can move cash into investments and record an investing outflow without consuming that amount in clinical operations. The June balance sheet contains the separate $99.296 million short-term-investment line. The operating and investing totals therefore need to be considered with the asset categories, rather than adding both flows and describing the result as a clinical burn rate.[2]

Dividing reported H1 operating cash use by six gives a calculated historical average of $2.559 million per month. That average describes the reported half-year, including its revenue-related receipts, working-capital changes and operating schedule. It is not a prospective monthly budget for expanding global Phase I studies or initiating later-stage development. A simple division of June liquidity by this historical average would create a mechanical coverage number, not a management-funded clinical plan.

Earnings tell a different story. The first-half net loss was $5.336 million, much smaller than the cash outflow from operations, while license-related revenue was $13.056 million. Differences between recognized revenue, payment timing, non-cash items and working capital mean the loss cannot be used as a direct proxy for cash consumption. The cash-flow statement is the appropriate starting point for examining the movement of cash.[2]

For future periods, the useful comparison is not just whether cash use rises or falls. Higher spending can be consistent with meaningful clinical progress if it produces enrolled cohorts and informative data. Lower spending can reflect efficiency, timing, reduced activity or a decision to deprioritize a program. The company already describes AN4005 prioritization and a continuing clinical expansion strategy, so interpretation should connect spending to the actual work accomplished.[2]

09 Revenue and expenses: licensing recognition is not a commercial oncology franchise

Adlai’s H1 2026 revenue of $13.056 million came entirely from its exclusive AN9025 license agreement with Jiangsu Aosaikang, primarily in connection with upfront payments and development milestone achievements. The comparable H1 2025 revenue was zero. This is evidence of an economic licensing relationship and recognized contractual income. It is not revenue from routine sales of an approved drug developed and marketed by Adlai.[2]

That distinction changes how the income statement should be interpreted. A licensing milestone can be substantial relative to a clinical-stage company’s expenses but may be linked to a specific development event. It does not necessarily recur every half-year at the same level. The relevant future questions include which obligations or milestones support recognition, when cash is received and what rights or future obligations accompany the license.

Research and development expense was $14.632 million in H1 2026, compared with $15.248 million a year earlier. Management attributes the decrease primarily to lower preclinical costs while major programs remained in early-stage development. General and administrative expense increased to $5.817 million from $4.066 million, with higher share-based compensation associated with option vesting identified as the main explanation. Reported operating loss was $5.769 million.[2]

The lower net loss, $5.336 million versus $18.335 million, therefore sits within a specific revenue and expense mix. It is not a standalone measure of therapeutic progress. A period with milestone-related revenue can show a much smaller loss even if the programs still require extensive clinical validation. Similarly, share-based compensation affects accounting costs and ownership economics differently from a cash payment.[2]

The annual report adds another reason to distinguish recognition from receipts. It describes $5 million of 2025 revenue recognized from an exclusive-option liability associated with a payment received in 2023 after the related project was discontinued and exercise of residual rights was considered remote. That accounting event was not a new $5 million operating receipt in 2025. The history shows why the financial story needs both contractual context and cash-flow information.[6]

10 Equity financing and the shareholder denominator

The August operating update says Adlai completed private placements with gross proceeds of $140 million in February 2026 and $150 million in April, before placement-agent fees and other expenses. The H1 financial statements separately report $223.141 million of financing cash inflow and $224.437 million of ordinary-share issuance in the statement of changes in equity. Those figures have different accounting scopes and cannot be treated as identical lines.[2]

The registration filings add share-level detail. The post-effective amendment to the Form F-3 filed on September 11, 2026 states that the February placement covered 64,615,386 Class A ordinary shares (21,538,462 ADSs) at $6.50 per ADS and the April placement 33,962,241 Class A ordinary shares (11,320,747 ADSs) at $13.25 per ADS. The same filing lists 25,384,617 Class A ordinary shares from the February placement as still to be issued to an entity to be formed and controlled by chairman and chief executive Yang Lu, upon satisfaction of the closing conditions of the securities purchase agreement, and computes selling-shareholder percentages on 218,578,427 ordinary shares: 193,193,810 issued and outstanding on September 11 plus that pending tranche. In a calculation by Merlintrader, 64,615,386 minus 25,384,617 leaves 39,230,769 February shares; added to the 33,962,241 April shares, that gives 73,193,010, the same figure as the increase in Class A shares between December 31, 2025 and June 30, 2026. In the same calculation, the pending tranche corresponds to about $55 million of the $140 million February headline at the placement price and to about 13.1% of the September 11 ordinary-share total. As of October 15, 2026, the company had not announced the closing of that tranche.[9]

For a financial assessment, the observed balance sheet is more useful than adding announced gross financing amounts to reported cash. June cash and short-term investments already reflect the period’s financing, operating and investing activity. Adding the financing headlines again would double count resources. Gross transaction proceeds are also different from net cash flow after relevant payments and other financing movements.

The comparative June statements report 176,203,813 Class A ordinary shares and 16,990,000 Class B ordinary shares outstanding at June 30, versus 103,010,803 Class A and the same 16,990,000 Class B at December 31, 2025. Combining the two classes within each of those balance-sheet dates gives a calculated 193,193,813 versus 120,000,803 ordinary shares, an increase of approximately 60.99%. This comparison uses the two classes stated in the same comparative financial-position table.[2]

Schedule 13G/A filings dated August 14, 2026 report holdings as of June 30, 2026. Cormorant Asset Management and Bihua Chen reported shared beneficial ownership of 3,978,229 ADSs, or 6.77%, while Venrock Healthcare Capital Partners entities reported 9,638,193 Class A ordinary shares, or 4.4%. The two filers used different share bases: Cormorant cited 142,241,572 Class A ordinary shares as of April 10, 2026 plus the ADSs sold in the April placement, while Venrock cited 218,578,430 Class A ordinary shares outstanding as of April 21, 2026, as reported in a July 20, 2026 prospectus supplement. Those percentages are therefore not directly comparable with each other or with the June ordinary-share total.[12][13]

The listed instrument requires another distinction. The annual report describes the ADS ratio as three Class A ordinary shares per ADS. An ordinary-share count is therefore not an ADS trading count, and Class B governance rights make the capitalization more than a single homogeneous share table. Calculating market value or per-share metrics requires the correct security unit, the relevant date and a denominator consistent with that unit.[6]

Employee options, restricted awards and incentive-plan capacity are additional categories, not synonyms for common shares already outstanding. The annual report contains outstanding awards and plan reserves with different conditions, while the June equity statement includes option exercise, restricted-share vesting and share-based compensation. Authorized capacity does not mean every reserved share has been issued, and accounting anti-dilution in a loss period does not make the underlying economic possibility disappear.[2][6]

Two authorizations frame future issuance capacity. The Form F-3 declared effective on April 28, 2026, and updated for the Singapore continuation by a post-effective amendment declared effective on September 15, 2026, covers possible sales by the company of up to $600 million of securities, including ADSs, Class A ordinary shares, debt securities, warrants, rights and units, together with the resale by selling shareholders of up to 98,577,627 Class A ordinary shares (32,859,209 ADSs) from the February and April placements. The company receives no proceeds from resales by selling shareholders, and the registered resale amount includes the 25,384,617-share tranche still to be issued; the $600 million amount is registered capacity, not an announced offering. At the extraordinary general meeting of September 30, 2026, shareholders passed all resolutions, including authority for the directors to allot and issue up to 90,000,000 Class A ordinary shares, with pre-emption rights waived, until the conclusion of the next annual general meeting or the end of the period within which it must be held, whichever is earlier. As of October 15, 2026, the company had not announced an offering under either authority.[8][9][10]

The funding reset is consequently both an asset and a cost. It gives Adlai resources to develop several programs, while existing holders share the future outcome with a larger denominator. A favorable development outcome must be considered in relation to that denominator and the subsequent capital required. Neither cash growth alone nor share-count growth alone determines the complete result.

11 Licenses, patent rights and development dependencies

Adlai’s pipeline involves rights obtained through agreements as well as internal development. The annual report describes the AN9025 relationship in designated Greater China territories and an AN0025 license from Eisai covering specified territories with exclusions. It also discusses development and intellectual-property arrangements involving other programs. Those agreements determine where a company can develop or commercialize an asset and what payments or other obligations may arise.[6]

Potential milestones and royalties need to retain their conditional character. A maximum contractual milestone amount is not the same as a current debt payable, a guaranteed future expense or cash already earned. The triggering events, territories, sublicensing rights, termination provisions and product-development responsibilities can matter more than the largest number in a summary. A licensing arrangement can fund one part of development while attaching future economic obligations to another.

Patent duration also needs a narrower reading than a single portfolio-wide expiry date. The annual report discusses different patent and application positions across AN9025, AN8025, AN4005 and AN0025, with expected terms and potential extensions varying by asset and jurisdiction. Applications, granted claims and licensed rights are distinct categories. An estimated expiration in a company filing is not a legal conclusion that every relevant claim remains enforceable to that date.[6]

The same operational discipline applies to manufacturing and trial execution. The annual report describes reliance on external manufacturers and research organizations, and the current RAS programs involve clinical work across several countries. Supplier performance, trial-site activation, recruitment and product quality can all influence timing. The cetuximab supply arrangements address a defined part of that operating chain, rather than every manufacturing or trial dependency.[1][2][6]

This is why a program should be evaluated as a connected development system. A molecule with promising biology still needs sufficient rights, a usable formulation and supply process, a protocol capable of answering the next question, and a budget to complete that work. A licensing or supply agreement can strengthen one link without proving the entire chain. The most informative future disclosures will connect those inputs to actual clinical progress.

12 Management, reporting quality and the Singapore continuation

The October 15 release quotes Dr. Archie Tse as president and head of research and development; the August financial update identifies Yang Lu as chief executive and chairman. These responsibilities sit at the center of the pipeline’s execution and capital-allocation decisions. Trial design and portfolio prioritization will determine what evidence the company’s strengthened balance sheet produces, while management’s financial reporting determines how clearly that execution can be assessed.[1][2]

The Singapore continuation completed on July 29 changes the parent company’s legal domicile and name, as reported in the August 19 filing. It does not by itself change the underlying scientific questions in the pipeline. The company’s global operations and cross-border development relationships remain relevant to trial execution, regulation, currency exposure and the movement of resources among entities.[3][6]

Reporting quality is a separate risk from clinical quality. The 2025 annual report describes a material weakness involving the application of IFRS to the accounting for an exclusive-option transaction and disclosure controls that were not effective at year-end. It describes revisions to historical financial reporting and remediation measures. Those are dated annual-report disclosures, not a conclusion that the same condition had or had not been remediated by October.[6]

The annual report also describes a dual-class structure and concentrated voting influence. Economic ownership and voting control can therefore differ. Additional Class A issuance can change the financial denominator without changing control proportionately. For ADS holders, the depositary structure, ordinary-share rights and the company’s constitutional arrangements are relevant alongside the number of securities in the market.[6]

Recent Form 4 filings report open-market ADS sales by insiders. Chief financial officer Xiaofeng Ye reported selling 6,000 ADSs on August 24, 2026 at $13.98 and 5,667 ADSs on August 26 at a weighted average price of $14.25, describing the sales as tax and liquidity management after restricted stock units vested on April 14, 2026. Director Ping Ji filed a Form 144 on September 18 covering the proposed sale of up to 80,000 ADSs and then reported sales totaling 15,214 ADSs between September 22 and September 30, at prices between $15.77 and $16.63. These are transactions by individual holders, not company issuance. In a calculation by Merlintrader, the 26,881 ADSs sold by the two insiders represent 80,643 Class A ordinary shares, about 0.04% of the 193,193,810 ordinary shares outstanding on September 11.[11][9]

The practical governance question is whether decision-making remains transparent as the portfolio expands. Useful evidence includes clear program priorities, consistent financial definitions, explicit distinction between company forecasts and completed milestones, and explanations of material changes in funding or development strategy. A relocation or a financing can support growth, but neither automatically resolves reporting, governance or execution risks.

13 Catalyst map, risks and what would falsify the reading

The announced calendar contains several different types of events. Adlai’s August guidance targets AN8025 dose-escalation completion by year-end 2026, initial daily-arm AN9025 Phase Ia data in H1 2027 with a possible early weekly-arm look, ARTEMIS topline in H1 2027 and initial AN4035 clinical data in H2 2027. It also anticipated an AN4005 expansion-cohort update at SITC 2026. Each is a company expectation and each addresses a different uncertainty.[2]

A dose-escalation completion milestone can establish readiness for a subsequent dose decision without establishing efficacy. An initial clinical presentation may contain a small or immature subgroup. A randomized Phase II topline result can address a specified comparison but still require detailed safety and durability information. Registry primary-completion estimates are another category: they describe planned study completion, not a guaranteed press-release date.[2][4][5]

The constructive reading would weaken if usable exposures proved intolerable, if activity lacked consistency in the intended populations, if expansion strategies repeatedly changed without a clear evidence-based explanation, or if capital consumption grew without producing meaningful clinical decisions. Those are criteria for interpreting future developments, not claims that such outcomes have occurred.

The cautious reading would weaken if the RAS programs demonstrated a reproducible relationship among target engagement, tolerability and durable activity, supported by a clear next-trial strategy. For AN4035, monotherapy and combination findings would need to clarify whether tumor-directed delivery creates a useful practical window. For AN9025, daily and weekly schedules would need to show how exposure and regimen selection support the intended clinical use.

Financial execution must accompany that evidence. The June resources provide room to test the programs, while debt, licensing obligations, trial costs and the larger share denominator remain part of the economic picture. A later financing is not automatically evidence of failure, just as a large cash balance is not proof of value creation. The assessment turns on what evidence and development capacity are obtained for the capital used.

Adlai Nortye’s central proposition is therefore a funded attempt to translate differentiated RAS delivery strategies into human evidence. The October supply agreements improve the operating definition of the AN4035 combination study, while the 2027 windows identify when management expects initial information. The decisive question is whether the data support a tolerable and clinically useful regimen, and whether subsequent capital allocation preserves a coherent path from that evidence to the next development step.